Enzymatica announces outcome of new rights issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, BELARUS, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR INVOLVE REQUIREMENTS FOR MEASURES OTHER THAN WHAT FOLLOWS BY SWEDISH LAW.

The Board of Directors of Enzymatica AB (”Enzymatica” or ”Company”) today announces the outcome of the new share issue with preferential rights for existing shareholders that was resolved by the Board of Directors on July 18, 2024, and subsequently approved by the extraordinary general meeting on August 6, 2024 (the “Rights issue”). The Rights issue was subscribed to 100 percent, and the Company will receive proceeds amounting to around SEK 132 million before issue costs. The Rights issue was subscribed for 61.1 percent with subscription rights, for 16.0 percent without subscription rights and for 22.9 percent through guarantee commitments by large shareholders in the Company, among them members of the Board of Directors and the CEO.

On September 11, 2024, the subscription period for the Rights issue ended. The final outcome shows that the Rights issue was subscribed to 61.1 percent with subscription rights, 16.0 percent without subscription rights, and 22.9 percent according to guarantee commitments from large shareholders. The subscription price in the Rights issue was SEK 1.90 per share and the Company will receive proceeds amounting to around SEK 132 million before issue costs.

“The fully subscribed rights issue is a statement of strength from Enzymatica. Despite a strained financial situation on the financial market, the company is now infused with SEK 132 million, which lays a stable foundation for geographic expansion, further clinical studies, and more. It shows that there is strong faith in both the company and our products”, said CEO Claus Egstrand.

Through the Rights Issue the share capital will increase from SEK 6,935,291 to 9,709,407.81. The total number of shares in the Company will increase from 173,382,220 to 242,735,108.

The allocation of shares subscribed without subscription rights has been carried out in accordance with the principles specified in the prospectus, which was prepared in connection with the Rights issue and published by the Company on August 26, 2024. Notification of allocation will be made through a settlement note sent to each subscriber. Allocated shares shall be paid for in accordance with the instructions on the settlement note. Nominee-registered shareholders will receive notification of allocation in accordance with instructions from their respective nominees. Only those who receive an allocation will be notified.

The last day for trading in paid-up subscribed shares (BTA) on Nasdaq First North Growth Market is expected to be September 23, 2024. The new shares are expected to be traded on Nasdaq First North Growth Market on or about September 30, 2024. The above is the final outcome of the Rights issue, thus no further press releases about the outcome of the Rights issue will be issued.

Advisors
Bergs Securities is the financial advisor and Setterwalls Law Firm is the legal advisor to Enzymatica in connection with the Rights issue.

For more information contact:

Claus Egstrand, CEO, Enzymatica AB
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com

Important information
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction where such offer would be considered illegal. This press release does not constitute an offer to sell or an offer to buy or subscribe for shares issued by the Company in any jurisdiction where such offer or invitation would be illegal. In a member state within the European Economic Area ("EEA"), shares referred to in the press release may only be offered in accordance with applicable exemptions under the Prospectus Regulation.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States, Hong Kong, Canada, Japan, New Zeeland, Russia, Belarus, Singapore, South Africa, Australia, or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

A prospectus regarding the Rights issue described in this release has been published by the Company on August 26, 2024. This release is however not a prospectus in accordance to the definition in the Prospectus Regulation. In accordance with article 2 k of the Prospectus Regulation this press release constitutes an advertisement. Complete information regarding the Rights issue can only be obtained through the Prospectus. Enzymatica has not authorized any offer to the public of shares or rights in any other member state of the EEA. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation. This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the new shares. Any investment decision in connection with the Rights issue must be made on the basis of all publicly available information relating to the Company and the Company's shares. Such information has not been independently verified by the financial adviser. The financial adviser is acting for the Company in connection with the transaction and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to its clients nor for giving advice in relation to the transaction or any other matter referred to herein.

Information to distributors
Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or

otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares in Enzymatica have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, Distributors should note that: the price of the shares in Enzymatica may decline and investors could lose all or part of their investment; the shares in Enzymatica offer no guaranteed income and no capital protection; and an investment in the shares in Enzymatica is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Rights issue.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in Enzymatica.

Each distributor is responsible for undertaking its own target market assessment in respect of the shares in Enzymatica and determining appropriate distribution channels.

Enzymatica AB is headquartered in Lund, Sweden, and is listed on Nasdaq First North Growth Market.
For more information, please visit www.enzymatica.com. Enzymatica’s Certified Adviser is Carnegie Investment Bank AB (publ).